Amneal's CREXONT Shows Over 3 Hours More 'Good On' Time in Parkinson's Patients, Strengthening Market Position
AMRX sits 99% above its 52-week low of $7.01.
Summary
Amneal Pharmaceuticals announced positive interim results from its Phase 4 ELEVATE-PD study for CREXONT® in Parkinson's disease, demonstrating significant clinical benefits. Patients switching to CREXONT experienced over 3 additional hours of daily "Good On" time and reduced "Off" time, with those switching from RYTARY seeing continuous "Good On" intervals nearly double. These findings, presented at the American Academy of Neurology, reinforce CREXONT's established efficacy and safety profile. This positive data is material for Amneal, as it could drive increased adoption and market share for CREXONT, a key product for the company. Investors will watch for longer-term outcomes and patient-reported results throughout 2026.
At the time of this announcement, AMRX was trading at $13.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $7.01 to $15.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.